Skip to main content

eflapegrastim

Generic: eflapegrastim·Brand: Rolvedon

eflapegrastim: sourced relationships with 1 company · 1 clinical trial tracked.

eflapegrastim evidence translation

What we can confirm

What it means

Source-backed records connect eflapegrastim to SPPI; that link alone does not prove the drug works.

What to watch

Watch trial status, endpoints, and the next source-backed update.
BioSniper AIPage evidence connected

Prepared research question

How could eflapegrastim → SPPI affect its developer, and what evidence supports the link?

Run cited research

Traceable citations · Unknowns marked

See linked entities and source evidence2 indications · 0 study sponsors

Related indications

Solid TumorsLymphoma

Study sponsors

No additional listed-company sponsor is linked.

Dated Pipeline Records (1)
CompanyDated record stage
SPECTRUM PHARMACEUTICALS INC (SPPI)
co_developer · Reported 2022-03-18 · Current development: unknownSource
Solid Tumors
Phase 2
Clinical Trial Registry Records (1)

A Multicenter, Open-Label, Phase 2 Study to Evaluate the Safety and Pharmacokinetics of Eflapegrastim in Pediatric Patients With Solid Tumors or Lymphomas and Treated With Myelosuppressive Chemotherapy

NCT04570423Registry updated 2026-05-22·Phase 2·SPPI
Recruiting

Primary endpoint: Number of Participants With Treatment Emergent Adverse Events (TEAEs)

Interventionalopen40 targetStarted 2021-05Completion 2027-105 sites · United StatesSpectrum Pharmaceuticals, Inc

Frequently asked questions

Which companies have sourced relationships with eflapegrastim?

eflapegrastim has dated SEC/FDA relationship records for SPECTRUM PHARMACEUTICALS INC.

How many clinical trials involve eflapegrastim?

BioSniper tracks 1 clinical trial involving eflapegrastim.